Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ).
Shanghai Henlius Biotech, Inc. has issued a clarification announcement regarding the closure of its register of members, specifying the requirements for lodging transfer documents and share certificates for registration by August 26, 2025. This announcement ensures that shareholders are informed of the necessary procedures, potentially impacting shareholder transactions and company operations.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and production of biopharmaceutical products. The company is involved in the healthcare industry, specializing in the creation of biosimilars and innovative biologic drugs.
Average Trading Volume: 1,347,932
Technical Sentiment Signal: Buy
Current Market Cap: HK$43.1B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.